Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2024-07-20
2025-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin
NCT02656589
MRD in High-risk EBC
NCT06566729
Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China
NCT03792529
Diagnostic and Prognostic Value of MicroRNA in Breast Cancer Patients
NCT04778202
ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies
NCT04265937
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Health donor group
In-situ detection for Micro-RNA
a new in-situ detection methods for Micro-RNA
Breast cancer group
In-situ detection for Micro-RNA
a new in-situ detection methods for Micro-RNA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
In-situ detection for Micro-RNA
a new in-situ detection methods for Micro-RNA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lei Dou
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shabei Xu, Dr.
Role: STUDY_DIRECTOR
Tongji Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20240771
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.